Abeona Therapeutics Stock Today
| ABEO Stock | USD 5.98 0.19 3.28% |
Performance2 of 100
| Odds Of DistressLess than 8
|
Abeona Therapeutics is selling at 5.98 as of the 23rd of November 2024; that is 3.28 percent increase since the beginning of the trading day. The stock's open price was 5.79. Abeona Therapeutics has only a 8 % chance of going through financial distress over the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Abeona Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of August 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of September 1980 | Category Healthcare | Classification Health Care |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. Abeona Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 43.47 M outstanding shares of which 2.64 M shares are presently shorted by private and institutional investors with about 10.79 trading days to cover. More on Abeona Therapeutics
Moving together with Abeona Stock
Moving against Abeona Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Abeona Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Vishwas MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, CAC Consumer Goods, CAC All Shares, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAbeona Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Abeona Therapeutics' financial leverage. It provides some insight into what part of Abeona Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abeona Therapeutics (ABEO) is traded on NASDAQ Exchange in USA. It is located in 6555 Carnegie Avenue, Cleveland, OH, United States, 44103 and employs 84 people. Abeona Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 259.96 M. Abeona Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 43.47 M outstanding shares of which 2.64 M shares are presently shorted by private and institutional investors with about 10.79 trading days to cover.
Abeona Therapeutics currently holds about 20.1 M in cash with (37.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38.
Check Abeona Therapeutics Probability Of Bankruptcy
Ownership AllocationAbeona Therapeutics holds a total of 43.47 Million outstanding shares. The majority of Abeona Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Abeona Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Abeona Therapeutics. Please pay attention to any change in the institutional holdings of Abeona Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Abeona Ownership Details
Abeona Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Walleye Trading Advisors, Llc | 2024-06-30 | 990.4 K | |
| Ikarian Capital, Llc | 2024-06-30 | 768.6 K | |
| 683 Capital Management Llc | 2024-06-30 | 600 K | |
| Citigroup Inc | 2024-06-30 | 490.3 K | |
| Blackrock Inc | 2024-06-30 | 446.4 K | |
| Simplify Asset Management Inc. | 2024-09-30 | 408.6 K | |
| Geode Capital Management, Llc | 2024-06-30 | 382.3 K | |
| Newtyn Management Llc | 2024-06-30 | 380 K | |
| Abrdn Plc | 2024-09-30 | 327 K | |
| Nantahala Capital Management, Llc | 2024-06-30 | 6.9 M | |
| Suvretta Capital Management, Llc | 2024-06-30 | 3.7 M |
Abeona Therapeutics Historical Income Statement
Abeona Stock Against Markets
Abeona Therapeutics Corporate Management
| Joseph Vazzano | Chief Officer | Profile | |
| Dmitriy MD | Chief Officer | Profile | |
| Brian Kevany | CTO VP | Profile | |
| Carl Denny | Senior Affairs | Profile | |
| Alison Hardgrove | Vice Resources | Profile | |
| Scott Santiamo | Director Communications | Profile |
Already Invested in Abeona Therapeutics?
The danger of trading Abeona Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abeona Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abeona Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abeona Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.38) | Return On Equity (1.27) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.